Cryptotanshinone Alleviates Nonalcoholic Fatty Liver Disease by Inhibiting NPC1L1-Mediated Intestinal Cholesterol Absorption
Preprint
- 30 January 2025
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Danshen, a well-known traditional Chinese medicine (TCM), has gained increasing attention due to the protective effects on nonalcoholic fatty liver disease (NAFLD). However, the molecular basis and working mechanism remain to be elucidated. Niemann-Pick C1-like 1 (NPC1L1) is the crucial target mediating intestinal cholesterol absorption and its inactivation has been shown to alleviate NAFLD. Thus, this study aimed to screen NPC1L1 inhibitors in Danshen and investigate the therapeutic effects on NAFLD . A high-throughput screening platform based on the stable Caco2 cell lines expressing human-NPC1L1 (hL1-Caco2) was developed, and we found that tanshinones (Tans), the liposoluble components in Danshen, inhibited NPC1L1-mediated cholesterol absorption in hL1-Caco2 cells . The hepatic steatosis in high-fat diet (HFD)-fed mice was also reduced by Tans treatment. To find the active compounds in Tans, activity-oriented separation was performed by combining the high-throughput screening platform and two-dimensional chromatographic techniques. Ultimately, c ryptotanshinone (CTS) was identified as a novel NPC1L1 inhibitor and profoundly decreased hepatic steatosis in HFD-fed mice. The binding modes and stability between CTS and NPC1L1 were confirmed by molecular docking and dynamics simulation . Taken together, our findings demonstrate for the first time that CTS, the liposoluble compound in Danshen, alleviates NAFLD by inhibiting NPC1L1-mediated intestinal cholesterol absorption , suggesting that inhibition of NPC1L1 with CTS may be a potential strategy for the treatment of NAFLD.Keywords
All Related Versions
This publication has 35 references indexed in Scilit:
- Salvianolic acid A attenuates non-alcoholic fatty liver disease by regulating the AMPK-IGFBP1 pathwayChemico-Biological Interactions, 2024
- Resmetirom: First ApprovalDrugs, 2024
- Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancerCell Metabolism, 2022
- Niemann-Pick C1-Like 1 inhibitors for reducing cholesterol absorptionEuropean Journal of Medicinal Chemistry, 2022
- Cholesterol-induced toxicity: An integrated view of the role of cholesterol in multiple diseasesCell Metabolism, 2021
- Mechanisms and disease consequences of nonalcoholic fatty liver diseaseCell, 2021
- Application of two‐dimensional liquid chromatography in the separation of traditional Chinese medicineJournal of Separation Science, 2019
- Sodium tanshinone IIA sulfonate ameliorates hepatic steatosis by inhibiting lipogenesis and inflammationBiomedicine & Pharmacotherapy, 2019
- Ezetimibe, an NPC1L1 inhibitor, is a potent Nrf2 activator that protects mice from diet-induced nonalcoholic steatohepatitisFree Radical Biology and Medicine, 2016
- Hepatic triglyceride content in individuals with reduced intestinal cholesterol absorption due to variants in Nieman Pick C1-like 1Hepatology, 2011